These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34801525)

  • 1. SIS3 suppresses osteoclastogenesis and ameliorates bone loss in ovariectomized mice by modulating Nox4-dependent reactive oxygen species.
    Pan W; Zheng L; Gao J; Ye L; Chen Z; Liu S; Pan B; Fang J; Lai H; Zhang Y; Ni K; Lou C; He D
    Biochem Pharmacol; 2022 Jan; 195():114846. PubMed ID: 34801525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells.
    Boudreau HE; Casterline BW; Rada B; Korzeniowska A; Leto TL
    Free Radic Biol Med; 2012 Oct; 53(7):1489-99. PubMed ID: 22728268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xanthotoxin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
    Dou C; Chen Y; Ding N; Li N; Jiang H; Zhao C; Kang F; Cao Z; Quan H; Luo F; Xu J; Dong S
    Osteoporos Int; 2016 Jul; 27(7):2335-2344. PubMed ID: 26809192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways.
    Sun Y; Liu Y; He W; Wang C; Tickner J; Kuek V; Zhou C; Wang H; Zou X; Hong Z; Yang F; Shao M; Chen L; Xu J
    J Cell Physiol; 2019 Jul; 234(7):11792-11804. PubMed ID: 30515822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curculigoside attenuates oxidative stress and osteoclastogenesis via modulating Nrf2/NF-κB signaling pathway in RAW264.7 cells.
    Liu M; Liu S; Zhang Q; Fang Y; Yu Y; Zhu L; Liu Y; Gong W; Zhao L; Qin L; Zhang Q
    J Ethnopharmacol; 2021 Jul; 275():114129. PubMed ID: 33878416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
    Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
    Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
    Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
    Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
    [No Abstract]   [Full Text] [Related]  

  • 10. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
    Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
    Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerium Oxide Nanoparticles Regulate Osteoclast Differentiation Bidirectionally by Modulating the Cellular Production of Reactive Oxygen Species.
    Yuan K; Mei J; Shao D; Zhou F; Qiao H; Liang Y; Li K; Tang T
    Int J Nanomedicine; 2020; 15():6355-6372. PubMed ID: 32922006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
    Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
    Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polymethoxy flavonoid sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors.
    Ohyama Y; Ito J; Kitano VJ; Shimada J; Hakeda Y
    PLoS One; 2018; 13(1):e0191192. PubMed ID: 29342179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation.
    Xu Y; Song D; Lin X; Peng H; Su Y; Liang J; Hai N; Zhao J; Liu Q
    Free Radic Biol Med; 2023 Feb; 196():121-132. PubMed ID: 36649902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
    Hu B; Sun X; Yang Y; Ying Z; Meng J; Zhou C; Jiang G; Li S; Wu F; Zhao X; Zhu H; Wu H; Cai X; Shi Z; Yan S
    FASEB J; 2019 Feb; 33(2):2574-2586. PubMed ID: 30285579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS.
    Zhou L; Chen X; Yan J; Li M; Liu T; Zhu C; Pan G; Guo Q; Yang H; Pei M; He F
    Osteoporos Int; 2017 Dec; 28(12):3325-3337. PubMed ID: 28956094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity.
    Meng J; Zhang W; Wang C; Zhang W; Zhou C; Jiang G; Hong J; Yan S; Yan W
    Biochem Pharmacol; 2020 Jan; 171():113715. PubMed ID: 31751538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
    Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
    Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.